<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00045422</url>
  </required_header>
  <id_info>
    <org_study_id>02-013</org_study_id>
    <secondary_id>CDR0000256469</secondary_id>
    <secondary_id>NCI-G02-2105</secondary_id>
    <nct_id>NCT00045422</nct_id>
  </id_info>
  <brief_title>Interferon Alfa and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia</brief_title>
  <official_title>A Phase II Open Label Study to Determine Safety and Efficacy of Interferon-alpha in Combination With Imantinib Mesylate (Gleevec) in Patients With Chronic Phase Chronic Myelogenous Leukemia Who Have Not Achieved a Complete Cytogenetic Response to Gleevec as a Single Agent</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Interferon alfa may interfere with the growth of cancer cells. Imatinib mesylate&#xD;
      may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth.&#xD;
      Combining interferon alfa with imatinib mesylate may kill more cancer cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of combining interferon alfa with imatinib&#xD;
      mesylate in treating patients who have chronic myelogenous leukemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine whether interferon alfa in combination with imatinib mesylate adds to the&#xD;
           hematologic, cytogenetic, and molecular response rates in patients with chronic phase&#xD;
           chronic myelogenous leukemia that is newly diagnosed or has not achieved a complete&#xD;
           cytogenetic response to imatinib mesylate alone.&#xD;
&#xD;
      OUTLINE: Patients receive oral imatinib mesylate (STI-571) once daily for 9 months. At 9&#xD;
      months, patients with more than 35% Philadelphia chromosome-positive (Ph+) cells in bone&#xD;
      marrow receive oral STI-571 twice daily for 3 more months. At 12 months, patients with more&#xD;
      than 35% Ph+ cells in bone marrow receive oral STI-571 once daily and interferon alfa&#xD;
      subcutaneously once daily. Treatment continues for at least 1 year in the absence of disease&#xD;
      progression or unacceptable toxicity. Patients with an appropriate HLA-matched donor may&#xD;
      choose to have a bone marrow transplantation at any time during the study.&#xD;
&#xD;
      Patients are followed every 6 months for 3 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 80 patients (60 without an HLA-matched donor and 20 with an&#xD;
      HLA-matched donor) will be accrued for this study within 5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2002</start_date>
  <completion_date type="Actual">October 2003</completion_date>
  <primary_completion_date type="Actual">October 2003</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Leukemia</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>recombinant interferon alfa</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>imatinib mesylate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of chronic phase chronic myelogenous leukemia&#xD;
&#xD;
               -  Cytogenetically confirmed Philadelphia chromosome-positive disease or other&#xD;
                  variant of t(9;22)&#xD;
&#xD;
                    -  No secondary chromosomal abnormalities&#xD;
&#xD;
               -  No more than 10% blasts in bone marrow&#xD;
&#xD;
               -  Newly diagnosed OR&#xD;
&#xD;
               -  Received prior imatinib mesylate as a single agent for no more than the past 9&#xD;
                  months without achieving a complete cytogenetic response&#xD;
&#xD;
          -  No evidence of extramedullary involvement except nodes, liver, or spleen&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  Any age&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-3&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Platelet count greater than 100,000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count greater than 1,500/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin no greater than 2 times upper limit of normal (ULN)&#xD;
&#xD;
          -  SGOT no greater than 2 times ULN&#xD;
&#xD;
          -  INR no greater than 1.5 times ULN*&#xD;
&#xD;
          -  PTT no greater than 1.5 times ULN* NOTE: * Except patients on anticoagulants&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine no greater than 2 times ULN&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Considered potentially reliable&#xD;
&#xD;
          -  No history of noncompliance to medical regimens&#xD;
&#xD;
          -  No other active malignancy requiring chemotherapy or radiotherapy&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective barrier-method contraception during and for at&#xD;
             least 3 months after study&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No prior interferon therapy&#xD;
&#xD;
          -  No prior stem cell or bone marrow transplantation&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No prior chemotherapy (except hydroxyurea and/or anagrelide to control counts)&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  At least 4 weeks since prior major surgery and recovered&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No concurrent grapefruit juice or grapefruit products&#xD;
&#xD;
          -  No concurrent warfarin&#xD;
&#xD;
          -  Concurrent low-molecular weight heparin allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ellin Berman, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>September 6, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>June 4, 2013</last_update_submitted>
  <last_update_submitted_qc>June 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 5, 2013</last_update_posted>
  <keyword>chronic myelogenous leukemia, BCR-ABL1 positive</keyword>
  <keyword>chronic phase chronic myelogenous leukemia</keyword>
  <keyword>childhood chronic myelogenous leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Leukemia, Myeloid, Chronic-Phase</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Imatinib Mesylate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

